[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
create a website
The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity. (2013). Cockburn, Iain ; Bosworth, Barry ; Frank, Richard ; Aitken, Murray L. ; Kleinrock, Michael ; Berndt, Ernst R. ; Shapiro, Bradley T..
In: NBER Working Papers.
RePEc:nbr:nberwo:19487.

Full description at Econpapers || Download paper

Cited: 6

Citations received by this document

Cites: 53

References cited by this document

Cocites: 48

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

  1. The unexpected consequences of generic entry. (2019). Siotis, Georges ; Ornaghi, Carmine ; Castanheira, Micael.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:68:y:2019:i:c:s0167629618305332.

    Full description at Econpapers || Download paper

  2. Determinants of US Prescription Drug Utilization using County Level Data. (2016). Okunade, Albert ; Chen, Weiwei ; Fofana, Demba ; Nianogo, Thierry .
    In: Health Economics.
    RePEc:wly:hlthec:v:25:y:2016:i:5:p:606-619.

    Full description at Econpapers || Download paper

  3. Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001–2007. (2016). Berndt, Ernst R. ; Conti, Rena .
    In: NBER Chapters.
    RePEc:nbr:nberch:13100.

    Full description at Econpapers || Download paper

  4. Estimating the cost of strategic entry delay in pharmaceuticals: The case of Ambien CR. (2016). Shapiro, Bradley T.
    In: Quantitative Marketing and Economics (QME).
    RePEc:kap:qmktec:v:14:y:2016:i:3:d:10.1007_s11129-016-9170-9.

    Full description at Econpapers || Download paper

  5. Reference pricing in the presence of pseudo-generics. (2015). Vasconcelos, Helder ; Rodrigues, Vasco ; Gonçalves, Ricardo ; Gonalves, Ricardo.
    In: International Journal of Health Economics and Management.
    RePEc:kap:ijhcfe:v:15:y:2015:i:3:p:281-305.

    Full description at Econpapers || Download paper

  6. Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007. (2014). Berndt, Ernst R. ; Conti, Rena M..
    In: NBER Working Papers.
    RePEc:nbr:nberwo:20016.

    Full description at Econpapers || Download paper

References

References cited by this document

  1. Aitken, Murray L. and Ernst R. Berndt [2011], “Medicare Part D at Age Five: What Has Happened to Seniors’ Prescription Drug Prices?”, Report by the IMS Institute for Healthcare Bioinformatics, July.
    Paper not yet in RePEc: Add citation now
  2. Aitken, Murray L., Ernst R. Berndt and David M. Cutler [2008], “Prescription Drug Spending Trends in the United States: Looking Beyond The Turning Point”, Health Affairs Web Exclusive 28(1):W151-60, 2009. Published online 16 December 2008, 10.1377/hlthaff.28.1.w151.
    Paper not yet in RePEc: Add citation now

  3. Alpert, Abby, Mark Duggan and Judith K. Hellerstein [2013], “Perverse Reverse Price Competition: Average Wholesale Prices and Medicaid Pharmaceutical Spending”, August. Available from lead author at aealpert@uci.edu. Cambridge, MA: National Bureau of Economic Research, Working Paper, forthcoming September. Forthcoming, Journal of Public Economics.

  4. Appelt, Silvia [2013], “Authorized Generic Entry Prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry”, Working Paper, University of Munich, May. Available from the author at silvia.appelt@lrz.uni-muenchen.de.
    Paper not yet in RePEc: Add citation now
  5. Avalere Health LLC [2010], “State Policies Regarding Generic Substitution, 2010”. Powerpoint presentation. Available online at www.avalerehealth.net/research/docs/Generic_Substitution.pdf.
    Paper not yet in RePEc: Add citation now
  6. Berndt, Ernst R. and Joseph P. Newhouse [2012], “Pricing and Reimbursement in US Pharmaceutical Markets”, ch. 8 in Patricia M. Danzon and Sean Nicholson, eds., The Oxford Handbook of the Economics of the Biopharmaceutical Industry, New York: Oxford University Press, 201-265.
    Paper not yet in RePEc: Add citation now

  7. Berndt, Ernst R. and Murray L. Aitken [2011], “Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation”, International Journal of the Economics of Business 18(2):177-201, July 2011.

  8. Berndt, Ernst R., David M. Cutler, Richard G. Frank, Zvi Griliches, Joseph P. Newhouse and Jack E. Triplett [2000], “Medical Care Prices and Output”, ch. 3 in Anthony Culyer and Joseph P. Newhouse, eds., Handbook of Health Economics, Amsterdam and New York: Elsevier Sciences B.V., Vol. 1A:11780.

  9. Berndt, Ernst R., Iain M. Cockburn and Zvi Griliches [1996], “Pharmaceutical Innovation and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs”, Brookings Papers on Economic Activity: Microeconomics 1996(2):1133-88.

  10. Berndt, Ernst R., Richard Mortimer, Ashoke M. Bhattacharjya, Andrew Parece and Edward Tuttle [2007], “Authorized Generic Drugs, Price Competition, and Consumers’ Welfare”, Health Affairs 26(3):790-799, May/June.
    Paper not yet in RePEc: Add citation now

  11. Branstetter, Lee G., Chirantan Chatterjee and Matthew J. Higgins [2011], “Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry”, Cambridge, MA: National Bureau of Economic Research, Working Paper 17188, June.

  12. Caves, Richard E., Michael D. Whinston and Mark A. Hurwitz [1991], “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry”, Brookings Papers on Economic Activity: Microeconomics, 1991, 1-66.
    Paper not yet in RePEc: Add citation now
  13. Centers for Medicare & Medicaid Services [2012]. “Survey of Retail Prices”, May 31. Available online at http://medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/PrescriptionDrugs /Survey-of-Retail-Prices.html.
    Paper not yet in RePEc: Add citation now
  14. Cook, Anna [1998], How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, Washington DC: The Congress of the United States, Congressional Budget Office. Available online at http://www.cbo.gov/.
    Paper not yet in RePEc: Add citation now
  15. Drug Channels [2011], “Ranbaxy Makes Three: The Battle for Generic Lipitor Profits”, December 1.
    Paper not yet in RePEc: Add citation now
  16. Drug Channels [2012], “Pfizer’s Lipitor Strategy and the 2012 Generic Monster”, March 15. Available online at http://www.drugchannels.net/2012/03/pfizers-lipitor-strategy-and-2012.html.
    Paper not yet in RePEc: Add citation now
  17. Drug Facts and Comparisons 2011 Edition [2011], St. Louis, MO: Wolters Kluwer Health, Inc.
    Paper not yet in RePEc: Add citation now

  18. Ellison, Glenn and Sara Fisher Ellison [2011], “Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration”, American Economic Journal: Microeconomics 3(1):1-36.

  19. Ellison, Sara Fisher, Iain M. Cockburn, Zvi Griliches and Jerry A. Hausman [1997], “Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins”, RAND Journal of Economics 28(3):426-46.
    Paper not yet in RePEc: Add citation now
  20. Federal Trade Commission [2002], Generic Drug Entry Prior to Patent Expiration: An FTC Study, July.
    Paper not yet in RePEc: Add citation now
  21. Federal Trade Commission [2009], Authorized Generics: An Interim Report of the Federal Trade Commission, June 24. Available online at http://www.ftc.gov/os/2009/06/P062105authorizedgenericsreport.pdf.
    Paper not yet in RePEc: Add citation now
  22. Federal Trade Commission [2011], Authorized Generic Drugs: Short-Term Effects and Long-Term Impact, August. Available online at http://www.ftc.gov/opa/2011/08/genericdrugs.shtm.
    Paper not yet in RePEc: Add citation now
  23. FiercePharma [2012], “Top 15 drug patent losses for 2013”, November 1. Available online at http://www.fiercepharma.com/special-reports/top-15-patent-expirations-2013.
    Paper not yet in RePEc: Add citation now
  24. Frank, Richard G. and David S. Salkever [1997], “Generic Entry and the Pricing of Pharmaceuticals”, Journal of Economics and Management Strategy 6(1):75-90.
    Paper not yet in RePEc: Add citation now
  25. Generic Pharmaceutical Association [2012], Generic Drug Savings in the U.S.: Savings $1 Trillion Over 10 Years, Fourth Annual Edition, August 2. Available online at www.gphaonline.org.
    Paper not yet in RePEc: Add citation now

  26. Generic Pharmaceutical Association [2013], “Generic Industry by the Numbers”, Generic Pharmaceutical Association 2012 Annual Report. Available online at www.gphaonline.org.

  27. Generics and Loss of Exclusivity 2013 23 Brill, Alex [2010], “Overspending on Multi-Source Drugs in Medicaid”, Washington DC: American Enterprise Institute, AEI Health Policy Studies Working Paper @2010-01, July 21. Available online at http://www.aei.org/paper/100127.
    Paper not yet in RePEc: Add citation now
  28. Generics and Loss of Exclusivity 2013 24 Frank, Richard G. and David S. Salkever [1992], “Pricing, Patent Loss and the Market for Pharmaceuticals”, Southern Economic Journal 59:165-79.
    Paper not yet in RePEc: Add citation now
  29. Generics and Loss of Exclusivity 2013 25 Medicaid Drug Rebate Program [2013], last updated August 15, 2013. Available online at http://www.medicaid.gov.
    Paper not yet in RePEc: Add citation now
  30. Generics and Loss of Exclusivity 2013 26 Wosinska, Marta and Robert S. Huckman [2004], “Generic Dispensing and Substitution in Mail and Retail Pharmacies”, Health Affairs – Web Exclusive, W4-409 to W4-416, posted 28 July 2004. Available online at www.healthaffairs.org. An abstract of the article was published in the hardcopy edition of Health Affairs 23(5):284, September/October 2004.
    Paper not yet in RePEc: Add citation now

  31. Grabowski, Henry G. and John M. Vernon [1992], “Brand Loyalty, Entry, and Price Competition in Pharmaceuticals After the 1984 Drug Act”, Journal of Law and Economics 35:331-350, October.

  32. Grabowski, Henry G. and Margaret K. Kyle [2007], “Generic Competition and Market Exclusivity Periods in Pharmaceuticals”, Managerial Decision and Economics 28:491-502.

  33. Grabowski, Henry G., Genia Long and Richard Mortimer [2011], “Implementation of the Biosimilar Pathway: Economic and Policy Issues”, Seton Hall Law Review 41(2):511-557 Grabowski, Henry G. and John M. Vernon [1996], “Longer Patents for Increased Generic Competition in the US: The Waxman-Hatch Act After One Decade”, PharmacoEconomics 10 Suppl2:110-123.
    Paper not yet in RePEc: Add citation now
  34. Grabowski, Henry G., Genia Long and Richard Mortimer [2013], “Biosimilars”, unpublished manuscript, Duke University, August. Forthcoming as ch. 12.8 in Patricia Danzon, ed., Encyclopedia of Health Economics, New York: Elsevier.
    Paper not yet in RePEc: Add citation now
  35. Grabowski, Henry G., Margaret K. Kyle, Richard Mortimer, Genia Long and Noam Kirson [2011], “Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act”, Health Affairs 30(11):2157-66, November.
    Paper not yet in RePEc: Add citation now

  36. Hemphill, C. Scott and Bhaven N. Sampat [2012], “Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals”, Journal of Health Economics 31(2):327-39, March.

  37. Hurwitz, Mark A. and Richard E. Caves [1988], “Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals”, Journal of Law and Economics 31:299-320, October.

  38. Huskamp, Haiden A., Julie M. Donohue, Catherine Koss, Ernst R. Berndt and Richard G. Frank [2008], “Generic Entry, Reformulations, and Promotion of SSRIs”, PharmacoEconomics 26(7):603-16.
    Paper not yet in RePEc: Add citation now
  39. IMS Institute for Healthcare Informatics [2013], Declining Medicine Use and Costs: For Better or Worse?, May. Available online at www.theimsinstitute.org.
    Paper not yet in RePEc: Add citation now
  40. Kelton, Christina M. L, Lenisa V. Chang and David H. Kreling [2013], “State Medicaid Programs Missed $220 Million in Uncaptured Savings As Generic Fluoxetine Came to Market, 2001-05”, Health Affairs 32(7):1204-11, July.
    Paper not yet in RePEc: Add citation now
  41. Olson, Luke M. and Brett W. Wendling [2013], “The Effect of Generic Drug Competition on Generic Drug Prices During the Hatch-Waxman 180-Day Exclusivity Period”, Washington DC: Federal Trade Commission, Bureau of Economics, Working Paper No. 317, April. Available online at bwendling@ftc.gov.
    Paper not yet in RePEc: Add citation now

  42. Panattoni, Laura E. [2011], “The Effect of Paragraph IV Decisions and Generic Entry Before Patent Expiration on Brand Pharmaceutical Firms”, Journal of Health Economics 30(1):126-45.

  43. Regan, Tracy L. [2008], “Generic Entry, Price Competition, and Market Segmentation in the Prescription Drug Market”, International Journal of Industrial Organization 26(4):930-48.

  44. Reiffen, David E. and Michael E. Ward [2005], “Generic Drug Industry Dynamics”, Review of Economics and Statistics 87(1):37-49.

  45. Reiffen, David E. and Michael E. Ward [2007], “’Branded Generics’ as a Strategy to Limit Cannibalization of Pharmaceutical Markets”, Managerial and Decision Economics 28:251.267.
    Paper not yet in RePEc: Add citation now

  46. Saha, Atanu, Henry G. Grabowski, Howard M. Birnbaum, Paul E. Greenberg and Oded Bizan [2006], “Generic Competition in the U.S. Pharmaceutical Industry”, International Journal of the Economics of Business 13(1):15-38, February.

  47. Scott Morton, Fiona M. [1999], “Entry Decisions in the Generic Pharmaceutical Industry”, The RAND Journal of Economics 30:421-440.
    Paper not yet in RePEc: Add citation now

  48. Scott Morton, Fiona M. [2000], “Barriers to Entry, Brand Advertising and Generic Entry in the U.S. Pharmaceutical Industry”, International Journal of Industrial Organization 18:1085-104.

  49. Smith, Aaron [2007], “Federal judge whacks generic Plavix”, CNN Money.com, June 10, 2007.
    Paper not yet in RePEc: Add citation now

  50. Somers, Julie [2010], Effects of Using Generic Drugs on Medicare’s Prescription Drug Spending, Washington DC: The Congress of the United States, Congressional Budget Office, September. Available online at http://www.cbo.gov/.

  51. U.S. Department of Labor, Bureau of Labor Statistics [2011], “The Pharmaceutical Industry: An Overview of CPI, PPI, and IPP Methodology”, Office of Prices & Living Conditions, October. Available online at http://www.bls.gov/ppi/pharmpricescomparison.pdf.
    Paper not yet in RePEc: Add citation now
  52. Wang, Xiangnong [2012], “Understanding Current Trends and Outcomes in Generic Drug Patent Litigation: An Empirical Investigation”, unpublished Masters’ honors thesis, Stanford University: Public Policy Program, May.
    Paper not yet in RePEc: Add citation now
  53. Wiggins, Steven N. and Robert Maness [2004], “Price Competition in Pharmaceuticals: The Case of AntiInfectives ”, Economic Inquiry 42(2):247-63.
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. Who should be regulated: Genuine producers or third parties?. (2023). Hattori, Keisuke ; Higashida, Keisaku.
    In: Journal of Economics.
    RePEc:kap:jeczfn:v:138:y:2023:i:3:d:10.1007_s00712-022-00808-5.

    Full description at Econpapers || Download paper

  2. Generic competition and the incentives for early-stage pharmaceutical innovation. (2022). Higgins, Matthew J ; Chatterjee, Chirantan ; Branstetter, Lee.
    In: Research Policy.
    RePEc:eee:respol:v:51:y:2022:i:10:s0048733322001184.

    Full description at Econpapers || Download paper

  3. Does NICE influence the adoption and uptake of generics in the UK?. (2021). Oneill, Phill ; Mestre-Ferrandiz, Jorge ; Bianchi, Simona ; Serra-Sastre, Victoria.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:22:y:2021:i:2:d:10.1007_s10198-020-01245-1.

    Full description at Econpapers || Download paper

  4. Does NICE influence the adoption and uptake of generics in the UK?. (2021). Oneill, Phill ; Mestre-Ferrandiz, Jorge ; Bianchi, Simona ; Serra-Sastre, Victoria.
    In: LSE Research Online Documents on Economics.
    RePEc:ehl:lserod:113639.

    Full description at Econpapers || Download paper

  5. Entry limiting agreements: First mover advantage, authorized generics and pay-for-delay deals. (2020). , Farasat ; Polanski, Arnold ; Mariuzzo, Franco.
    In: Working Paper series, University of East Anglia, Centre for Competition Policy (CCP).
    RePEc:uea:ueaccp:2015_05v4.

    Full description at Econpapers || Download paper

  6. Does Medicare Reimbursement Drive Up Drug Launch Prices?. (2020). Ridley, David ; Lee, Chung-Ying.
    In: The Review of Economics and Statistics.
    RePEc:tpr:restat:v:102:y:2020:i:5:p:980-993.

    Full description at Econpapers || Download paper

  7. Privatizing Plaintiffs: How Medicaid, the False Claims Act, and Decentralized Fraud Detection Affect Public Fraud Enforcement Efforts. (2020). Perez, Victoria ; Nguyen, Thuy.
    In: Journal of Risk & Insurance.
    RePEc:bla:jrinsu:v:87:y:2020:i:4:p:1063-1091.

    Full description at Econpapers || Download paper

  8. Brand versus generic: addressing non‐adherence, secular trends and non‐overlap. (2020). Murimi, Irene B ; Hunt, Lamar ; Varadhan, And Ravi ; Scharfstein, Daniel O ; Seamans, Marissa J ; Segal, Jodi B.
    In: Journal of the Royal Statistical Society Series A.
    RePEc:bla:jorssa:v:183:y:2020:i:4:p:1461-1478.

    Full description at Econpapers || Download paper

  9. Entry limiting agreements: First‐mover advantage, authorized generics, and pay‐for‐delay deals. (2020). Mariuzzo, Franco ; Polanski, Arnold.
    In: Journal of Economics & Management Strategy.
    RePEc:bla:jemstr:v:29:y:2020:i:3:p:516-542.

    Full description at Econpapers || Download paper

  10. Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets. (2019). Berndt, Ernst R ; Conti, Rena M.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26194.

    Full description at Econpapers || Download paper

  11. Private vs. Public Provision of Social Insurance: Evidence from Medicaid. (2019). Vabson, Boris ; Prinz, Daniel ; Layton, Timothy ; Maestas, Nicole.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26042.

    Full description at Econpapers || Download paper

  12. Who cares about a label? The effect of pediatric labeling changes on prescription drug utilization. (2019). Schmitt, Matt ; Ody, Christopher.
    In: International Journal of Health Economics and Management.
    RePEc:kap:ijhcfe:v:19:y:2019:i:3:d:10.1007_s10754-019-09265-y.

    Full description at Econpapers || Download paper

  13. Copyright and Generic Entry in Book Publishing. (2019). Reimers, Imke.
    In: American Economic Journal: Microeconomics.
    RePEc:aea:aejmic:v:11:y:2019:i:3:p:257-84.

    Full description at Econpapers || Download paper

  14. The effects of state‐level pharmacist regulations on generic substitution of prescription drugs. (2018). Barthold, Douglas ; Song, Yan.
    In: Health Economics.
    RePEc:wly:hlthec:v:27:y:2018:i:11:p:1717-1737.

    Full description at Econpapers || Download paper

  15. An Evaluation of the CPI Indexes for Prescription Drugs. (2018). Bosworth, Barry ; Berndt, Ernst R ; Koepcke, Eric ; Kleinrock, Michael ; Bieler, John.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:24210.

    Full description at Econpapers || Download paper

  16. Estimating the Causal Effect of Entry on Generic Drug Prices Using Hatch–Waxman Exclusivity. (2018). Wendling, Brett W ; Olson, Luke M.
    In: Review of Industrial Organization.
    RePEc:kap:revind:v:53:y:2018:i:1:d:10.1007_s11151-018-9627-y.

    Full description at Econpapers || Download paper

  17. Price competition in pharmaceuticals – Evidence from 1303 Swedish markets. (2018). Granlund, David ; Bergman, Mats A.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:61:y:2018:i:c:p:1-12.

    Full description at Econpapers || Download paper

  18. The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act. (2017). Carroll, Norman V ; Tehrani, Ali Bonakdar .
    In: Applied Health Economics and Health Policy.
    RePEc:spr:aphecp:v:15:y:2017:i:4:d:10.1007_s40258-017-0314-1.

    Full description at Econpapers || Download paper

  19. A Dose of Managed Care: Controlling Drug Spending in Medicaid. (2017). Dranove, David ; Starc, Amanda ; Ody, Christopher.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:23956.

    Full description at Econpapers || Download paper

  20. Consumer Learning and the Entry of Generic Pharmaceuticals. (2017). Bairoliya, Neha ; Petrin, Amil ; McCullough, Jeffrey S ; Karaca-Mandic, Pinar.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:23662.

    Full description at Econpapers || Download paper

  21. The Landscape of US Generic Prescription Drug Markets, 2004-2016. (2017). Berndt, Ernst R ; Murphy, Stephen J ; Conti, Rena M.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:23640.

    Full description at Econpapers || Download paper

  22. Do health insurers innovate? Evidence from the anatomy of physician payments. (2017). Gottlieb, Joshua ; Clemens, Jeffrey ; Molnar, Timea Laura .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:55:y:2017:i:c:p:153-167.

    Full description at Econpapers || Download paper

  23. Squeezing the Last Drop Out of Your Suppliers: An Empirical Study of Market-Based Purchasing Policies for Generic Pharmaceuticals. (2017). Bergman, Mats A ; Rudholm, Niklas ; Granlund, David.
    In: Oxford Bulletin of Economics and Statistics.
    RePEc:bla:obuest:v:79:y:2017:i:6:p:969-996.

    Full description at Econpapers || Download paper

  24. When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization. (2017). Schmitt, Matt ; Ody, Christopher ; Dafny, Leemore.
    In: American Economic Journal: Economic Policy.
    RePEc:aea:aejpol:v:9:y:2017:i:2:p:91-123.

    Full description at Econpapers || Download paper

  25. When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization. (2016). Schmitt, Matt ; Dafny, Leemore ; Ody, Christopher.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:22745.

    Full description at Econpapers || Download paper

  26. Mitigation of Perverse Incentives in Professional Sports Leagues with Reverse-Order Drafts. (2016). Lenten, Liam.
    In: Review of Industrial Organization.
    RePEc:kap:revind:v:49:y:2016:i:1:d:10.1007_s11151-015-9494-8.

    Full description at Econpapers || Download paper

  27. Private versus social incentives for pharmaceutical innovation. (2016). Perez-Castrillo, David ; Macho-Stadler, Ines ; González, Paula ; Gonzalez, Paula.
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:50:y:2016:i:c:p:286-297.

    Full description at Econpapers || Download paper

  28. Estimating the value of generic entry and intellectual property litigation in the pharmaceutical market. (2016). Arai, Koki ; Akematsu, Yuji .
    In: Japan and the World Economy.
    RePEc:eee:japwor:v:40:y:2016:i:c:p:16-20.

    Full description at Econpapers || Download paper

  29. Do Reverse Payment Settlements Constitute an Anticompetitive Pay-for-Delay?. (2015). Starr, Martha ; McGuire, Thomas G ; Drake, Keith M.
    In: International Journal of the Economics of Business.
    RePEc:taf:ijecbs:v:22:y:2015:i:2:p:173-200.

    Full description at Econpapers || Download paper

  30. The Anatomy of Physician Payments: Contracting Subject to Complexity. (2015). Gottlieb, Joshua ; Clemens, Jeffrey ; Molnar, Timea Laura .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:21642.

    Full description at Econpapers || Download paper

  31. Private versus Social Incentives for Pharmaceutical Innovation. (2015). Perez-Castrillo, David ; Macho-Stadler, Ines ; González, Paula ; Gonzalez, Paula.
    In: CESifo Working Paper Series.
    RePEc:ces:ceswps:_5672.

    Full description at Econpapers || Download paper

  32. Private versus Social Incentives for Pharmaceutical Innovation. (2015). Perez-Castrillo, David ; Macho-Stadler, Ines ; González, Paula ; Gonzalez, Paula.
    In: Working Papers.
    RePEc:bge:wpaper:860.

    Full description at Econpapers || Download paper

  33. THERAPEUTIC SUBSTITUTION POST‐PATENT EXPIRY: THE CASES OF ACE INHIBITORS AND PROTON PUMP INHIBITORS. (2014). Vandoros, Sotiris.
    In: Health Economics.
    RePEc:wly:hlthec:v:23:y:2014:i:5:p:621-630.

    Full description at Econpapers || Download paper

  34. Antihypertensive Medication Classes Used among Medicare Beneficiaries Initiating Treatment in 2007–2010. (2014). Muntner, Paul ; Oparil, Suzanne ; Kilgore, Meredith L ; Diaz, Keith M ; Huang, Lei ; Shimbo, Daichi ; Kent, Shia T.
    In: PLOS ONE.
    RePEc:plo:pone00:0105888.

    Full description at Econpapers || Download paper

  35. Do Reverse Payment Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?. (2014). Starr, Martha ; Drake, Keith M. ; McGuire, Thomas.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:20292.

    Full description at Econpapers || Download paper

  36. Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995–2007. (2014). Lopez-Valcarcel, Beatriz Gonzalez ; Puig-Junoy, Jaume.
    In: Health Policy.
    RePEc:eee:hepoli:v:116:y:2014:i:2:p:170-181.

    Full description at Econpapers || Download paper

  37. Competition in prescription drug markets: the roles of trademarks, advertising, and generic names. (2013). Lobo, Félix ; Feldman, Roger.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:14:y:2013:i:4:p:667-675.

    Full description at Econpapers || Download paper

  38. Pharmaceutical Followers. (2013). Ridley, David ; Ellickson, Paul ; Landry, Peter ; Arcidiacono, Peter .
    In: NBER Working Papers.
    RePEc:nbr:nberwo:19522.

    Full description at Econpapers || Download paper

  39. The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity. (2013). Cockburn, Iain ; Bosworth, Barry ; Frank, Richard ; Aitken, Murray L. ; Kleinrock, Michael ; Berndt, Ernst R. ; Shapiro, Bradley T..
    In: NBER Working Papers.
    RePEc:nbr:nberwo:19487.

    Full description at Econpapers || Download paper

  40. The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales following Loss of Exclusivity. (2013). Bosworth, Barry ; Frank, Richard ; Aitken, Murray L. ; Kleinrock, Michael ; Cockburn, Iain ; Berndt, Ernst R. ; Shapiro, Bradley.
    In: NBER Chapters.
    RePEc:nbr:nberch:13094.

    Full description at Econpapers || Download paper

  41. Pharmaceutical followers. (2013). Ridley, David ; Landry, Peter ; Arcidiacono, Peter ; Ellickson, Paul B..
    In: International Journal of Industrial Organization.
    RePEc:eee:indorg:v:31:y:2013:i:5:p:538-553.

    Full description at Econpapers || Download paper

  42. The effects of price regulation of pharmaceutical industry margins: A structural estimation for anti-ulcer drugs in France.. (2012). Lasio, Laura ; Dubois, Pierre.
    In: Health, Econometrics and Data Group (HEDG) Working Papers.
    RePEc:yor:hectdg:12/18.

    Full description at Econpapers || Download paper

  43. Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010. (2012). Dubois, Pierre ; Berndt, Ernst .
    In: TSE Working Papers.
    RePEc:tse:wpaper:25744.

    Full description at Econpapers || Download paper

  44. Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010. (2012). Dubois, Pierre ; Berndt, Ernst .
    In: IDEI Working Papers.
    RePEc:ide:wpaper:25732.

    Full description at Econpapers || Download paper

  45. Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010. (2012). Dubois, Pierre ; Berndt, Ernst R.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:9140.

    Full description at Econpapers || Download paper

  46. Diffusion of New Drugs in the Post-TRIPS Era. (2011). Cockburn, Iain ; Berndt, Ernst ; Blalock, Nathan .
    In: International Journal of the Economics of Business.
    RePEc:taf:ijecbs:v:18:y:2011:i:2:p:203-224.

    Full description at Econpapers || Download paper

  47. The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection. (2011). Grabowski, Henry .
    In: International Journal of the Economics of Business.
    RePEc:taf:ijecbs:v:18:y:2011:i:2:p:161-176.

    Full description at Econpapers || Download paper

  48. A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets. (2011). Newhouse, Joseph ; Berndt, Ernst R. ; McGuire, Thomas.
    In: Forum for Health Economics & Policy.
    RePEc:bpj:fhecpo:v:14:y:2011:i:2:n:10.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2024-12-26 16:02:14 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2023. Contact: CitEc Team.